Form 4 Filing for Aquestive Therapeutics, Inc.

Peter E. Boyd, Chief People Officer of Aquestive Therapeutics, Inc., was granted 60,000 Performance Stock Units (PSUs) on March 7, 2025. These PSUs are contingent and represent a right to receive one share of the Company's common stock. The performance period for these PSUs is from March 7, 2025, to March 7, 2028. If the performance conditions are met, the PSUs will vest in full on March 7, 2028. The performance price is determined by the 30-day average Nasdaq closing price over specific periods: the first is the 30-day average ending the day before the second anniversary of the grant date, and the second is the highest 30-day average Nasdaq closing price during the third year after the grant date. This filing was submitted late due to an administrative oversight.